SGLT2 Inhibitors in Type 2 DM: A Cardiorenal "Game-Changer"

"Cardio-renal Risk Reduction Across the Spectrum of Type 2 DM" presented by Anip BansalПодробнее

SGLT2 Inhibitors in Type 2 DM: A Cardiorenal "Game-Changer"Подробнее

Webinar #1: The Multiple Effects Of SGLT2 Inhibitors On Cardio–Renal–Metabolic System In T2 DiabetesПодробнее

SGLT-2 Inhibitors for Type 2 Diabetes - Amel Arnaout, MDПодробнее

SGLT2 Inhibitors for DiabeticsПодробнее

SGLT 2 Inhibitors A Game Changer | Diabetes Treatment | Diabetes | Kidney Disease | KidneyПодробнее

How does Dapagliflozin work? Understanding SGLT2 inhibitors.Подробнее

SGLT-2 Inhibitors, Explained: How They Work, Their Benefits and RisksПодробнее

Initiating and Managing SGLT2 Inhibitors in Type 2 Diabetes WebinarПодробнее

Dr Julie Lovshin - SGLT2i Cardiorenal mechanisms in diabetes and beyond - summary presentationПодробнее

The Daily Debate - SGLT-2 Inhibitors and T1DПодробнее

SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trialПодробнее

SGLT2 Inhibitors are Associated With Reduced CV Disease in Type 2 DiabetesПодробнее

Why SGLT2 Inhibitors Cause Euglycemic DKAПодробнее

ADA 2018: SGLT2 Inhibitors in the Management of Type 2 DiabetesПодробнее

SGLT2 inhibition in type 1 diabetes | Lori BerardПодробнее

2 Minute Update: Do SGLT2 inhibitors prevent progression to dialysis?Подробнее

Dr Julie Lovshin - SGLT2i Cardiorenal mechanisms in diabetes and beyondПодробнее

Using SGLT2-inhibitors to treat cardiac patients with diabetesПодробнее

SGLT2 Inhibitors: CV Outcomes Data in Type 2 DiabetesПодробнее

SGLT2 Inhibition and CVD Outcomes in Type 2 DiabetesПодробнее